A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)

Clicks: 455
ID: 266493
1995
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #4 of 28 articles by views in Blood

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The treatment of adult patients greater than 55 to 70 years of age with acute myelogenous leukemia (AML) is associated with a treatment-related mortality of approximately 25%. This prospective, double-blind randomized study was designed to see if the use of granulocyte-macrophage colony stimulating …
Reference Key
jm1995blooda Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rowe JM;Andersen JW;Mazza JJ;Bennett JM;Paietta E;Hayes FA;Oette D;Cassileth PA;Stadtmauer EA;Wiernik PH;;
Journal Blood
Year 1995
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/7605984
Keywords
leukemia National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support u.s. gov't adult female male aged middle aged Remission Induction Prospective Studies P.H.S. Clinical Trial Phase III Randomized Controlled Trial Double-Blind Method Multicenter Study length of stay acute disease Survival Analysis neutropenia / chemically induced combined modality therapy antineoplastic combined chemotherapy protocols / adverse effects cytarabine / administration & dosage disease-free survival recombinant proteins / therapeutic use myeloid / drug therapy antineoplastic combined chemotherapy protocols / therapeutic use p h wiernik immunologic factors / therapeutic use* pmid:7605984 j m rowe j w andersen bone marrow examination cytarabine / adverse effects daunorubicin / administration & dosage daunorubicin / adverse effects granulocyte-macrophage colony-stimulating factor / therapeutic use* myeloid / mortality myeloid / therapy* neutropenia / therapy*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.